Predicting Bevirimat resistance of HIV-1 from genotype

Background: Maturation inhibitors are a new class of antiretroviral drugs. Bevirimat (BVM) was the first substance in this class of inhibitors entering clinical trials. While the inhibitory function of BVM is well established, the molecular mechanisms of action and resistance are not well understood. It is known that mutations in the regions CS p24/p2 and p2 can cause phenotypic resistance to BVM. We have investigated a set of p24/p2 sequences of HIV-1 of known phenotypic resistance to BVM to test whether BVM resistance can be predicted from sequence,

• Type: Journal
• Year: 2010
• Where: BMCBI
• Authors: Dominik Heider, Jens Verheyen, Daniel Hoffmann
• Keywords: Antiretroviral Drugs, BMCBI 2010, Maturation Inhibitors, Phenotypic Resistance